Application of ginsenoside Rg5 in preparation of products for preventing and treating anemia

Abstract

The invention provides application of the ginsenoside Rg5 in preparation of products for preventing and treating anemia, particularly application of the ginsenoside Rg5 in preparation of products for preventing and treating hemolytic anemia, a new thought is provided for research and development of drugs for preventing and treating anemia, the ginsenoside Rg5 also provides application of the ginsenoside Rg5 in preparation of health care products for preventing and treating anemia, and the ginsenoside Rg5 is easy to obtain and low in cost. And full development and utilization of medicinal material resources can be promoted. The efficacy of ginsenoside Rg5 in improving anemia is specifically shown by increasing the dyeing intensity of heart red blood cells.

Description

Technical Field

[0001] The present invention relates to a new application of ginsenoside Rg5, and relates to the application of ginsenoside Rg5 in preparing products for preventing and treating anemia. Background Art

[0002] Anemia occurs when the body doesn't produce enough hemoglobin, a protein that carries oxygen to red blood cells and tissues throughout the body. When this happens, a person may feel weak and exhausted, depressed, and irritable.

[0003] Hemolytic anemia (HA), also known as hemolytic disease or hemolytic disorder, is a type of anemia caused by the rapid destruction of red blood cells, resulting in a decrease in the blood's red blood cell count and exceeding the bone marrow's ability to compensate. The causes of hemolytic anemia are primarily categorized as inherent red blood cell abnormalities and external factors. Any factor that accelerates red blood cell destruction can contribute to the disease. Autoimmune hemolytic anemia is a common type.

[0004] At present, the existing literature reports on ginsenoside Rg5 are mostly about anti-cancer and anti-tumor effects. There is no report that ginsenoside Rg5 can prevent and treat anemia, especially hemolytic anemia. Summary of the Invention

[0005] The present invention aims to use ginsenoside Rg5 in the preparation of products for the prevention and treatment of anemia, providing new ideas for the development of drugs for the prevention and treatment of hemolytic anemia. Ginsenoside Rg5 is readily available, which can promote the full development and utilization of medicinal resources. To achieve the above objectives, the present invention is implemented through the following technical solutions:

[0006] Application of ginsenoside Rg5 in the preparation of products for preventing and treating anemia.

[0007] Application of ginsenoside Rg5 in the preparation of products for preventing and treating hemolytic anemia.

[0008] The aforementioned ginsenoside Rg5 is used in the preparation of a product for preventing, treating and improving hemolytic anemia, wherein the prevention and treatment of hemolytic anemia is specifically manifested in increasing the staining intensity of cardiac red blood cells.

[0009] The molecular formula of the aforementioned ginsenoside Rg5 is: 42 H 70 O 12 , molecular weight: 766.998, structural formula:

[0010]

[0011] The aforementioned products include medicines or health products.

[0012] The preparation method of the above-mentioned product is to combine ginsenoside Rg5 with acceptable excipients in medicine, process it according to conventional methods, and prepare corresponding pharmaceutical preparations or health products.

[0013] The dosage forms of the aforementioned products include tablets, capsules, granules, oral liquids or pills.

[0014] A product for preventing and treating hemolytic anemia is provided, wherein the raw materials of the product contain ginsenoside Rg5.

[0015] A product for preventing, treating and improving hemolytic anemia is provided, wherein the product is mainly prepared from ginsenoside Rg5.

[0016] Compared with the prior art, the present invention has the following beneficial effects:

[0017] 1. The present invention discloses the use of ginsenoside Rg5 in the preparation of products for preventing and treating anemia. Experiments of the present invention have shown that ginsenoside Rg5 has the effect of improving anemia, which is specifically manifested by increasing the staining intensity of cardiac red blood cells.

[0018] Experimental example

[0019] 1. Testing materials

[0020] 1.1. Sample preparation information

[0021] Ginsenoside Rg6, ginsenoside Rk3, ginsenoside Rh4, ginsenoside Rg5, ginsenoside Rk1, ginsenoside Rg4 and 20-S ginsenoside Rg3, the solvent is DMSO (dimethyl sulfoxide).

[0022] Positive control: Shengxuening tablets, hereinafter referred to as Shengxuening tablets, are brown-red tablets, batch number 20240710, produced by Wuhan United Pharmaceutical Co., Ltd., and the solvent is standard dilution water.

[0023] Experimental Animals

[0024] Zebrafish were reared in fish farming water at 28°C (water quality: 200 mg of instant sea salt added to 1 L of reverse osmosis water, conductivity 450-550 μS / cm; pH 6.5-8.5; hardness 50-100 mg / L of CaCO3). They were bred and provided by our company's fish farming center. The experimental animal use license number is: SYXK(Zhejiang)2022-0004. The breeding and management of zebrafish complies with the requirements of the international AAALAC accreditation (certification number: 001458) and the IACUC ethics review number is: IACUC-2025-11444-01.

[0025] 1.3. Instruments, consumables, and reagents

[0026] Dissecting microscope (SZX7, OLYMPUS, Japan); CCD camera (VertA1, Shanghai Tusen Vision Technology Co., Ltd., China); precision electronic balance (CP214, OHAUS, USA); 6-well plate (Zhejiang Bellanbo Biotechnology Co., Ltd., China).

[0027] Methylcellulose (Batch No. C2004046, Shanghai Aladdin Biochemical Technology Co., Ltd., China); phenylhydrazine (Batch No. YH0170509, Shanghai Yihe Biotechnology Co., Ltd., China); o-dianisidine (Batch No. MKBX3619V, Sigma, USA); anhydrous sodium acetate (Batch No. F20090306, Sinopharm Chemical Reagent Co., Ltd., China); anhydrous ethanol (Batch No. 20220414, Shanghai Aladdin Biochemical Technology Co., Ltd., China).

[0028] 2. Detection Method

[0029] 2.1. Evaluation of efficacy in improving anemia

[0030] Wild-type AB zebrafish, 4 days post-fertilization (dpf), were randomly selected and plated in 6-well plates. Thirty zebrafish were treated in each well (experimental group). Samples (concentrations shown in Table 1) were administered in water, along with a positive control, Shengxuening tablets, at 250 μg / mL. A normal control group and a model control group were also established, with a volume of 3 mL per well. After treatment at 28°C for 6 hours, all experimental groups, except the normal control group, were administered phenylhydrazine in water to establish a zebrafish hemolytic anemia model. After one day of treatment at 28°C, groups without zebrafish mortality (a maximum of three groups, a minimum of one) were selected for o-dianisidine staining. Eight zebrafish were randomly selected from each experimental group and photographed under a dissecting microscope. Data were acquired using NIS-Elements D3.20 advanced image processing software. The intensity of zebrafish cardiac erythrocyte staining was analyzed, and statistical analysis of this indicator was used to evaluate the anemia-modifying efficacy of the samples. Statistical results are expressed as mean ± SE. Statistical analysis was performed using SPSS 26.0 software, and p < 0.05 indicated that the difference was statistically significant.

[0031] 3. Test results

[0032] 3.1. Evaluation of efficacy in improving anemia

[0033] Under the experimental conditions, ginsenoside Rg5 has the effect of improving anemia, which is specifically manifested by increasing the staining intensity of cardiac red blood cells. Ginsenoside Rk1, 20-S ginsenoside Rg3, ginsenoside Rg4, ginsenoside Rg6, ginsenoside Rh4, and ginsenoside Rk3 have no obvious effect in improving hemolytic anemia. See Table 1, Table 2, Figure 1 、 Figure 2、 Figure 3 and Figure 4 .

[0034] Table 1. Results of the evaluation experiment on the efficacy of samples in improving anemia (n=8)

[0035]

[0036] Compared with the model control group, ***p<0.001

[0037] Table 2. Results of the experimental evaluation of the efficacy of ginsenoside Rg5 in improving anemia (n=8)

[0038]

[0039] Compared with the model control group, **p<0.01, ***p<0.001

[0040] 4. Test conclusion

[0041] Under the experimental conditions of this study, ginsenoside Rg5, provided by Guizhou University of Traditional Chinese Medicine, showed an improvement in anemia, as evidenced by increased staining intensity of cardiac red blood cells. Ginsenosides Rk1, 20-S ginsenoside Rg3, ginsenoside Rg4, ginsenoside Rg6, ginsenoside Rh4, and ginsenoside Rk3 showed no significant improvement in hemolytic anemia. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] Figure 1 : Typical images of zebrafish heart erythrocyte staining intensity after sample treatment (the blue dotted area indicates the analysis site);

[0043] Figure 2 : Typical images of zebrafish heart red blood cell staining intensity after ginsenoside Rg5 treatment;

[0044] Figure 3 : The staining intensity of zebrafish heart red blood cells after sample treatment was compared with that of the model control group (***p<0.001);

[0045] Figure 4 : The staining intensity of zebrafish cardiac erythrocytes after ginsenoside Rg5 treatment was compared with that in the model control group (**p<0.01, ***p<0.001). DETAILED DESCRIPTION

[0046] The present invention will be further described below with reference to the accompanying drawings and examples, but they are not intended to limit the present invention.

[0047] Example 1. Ginsenoside Rg5 (purchased from the market) was added with appropriate amounts of conventional excipients, mixed, granulated, dried, and compressed into tablets. Each tablet contained 10 mg of ginsenoside Rg5.

[0048] Dosage and Administration: Take this preparation twice a day, 2 tablets each time.

[0049] Treatment of diseases: used to prevent and treat anemia, especially hemolytic anemia.

[0050] Example 2. Ginsenoside Rg5 (purchased from the market) was added with appropriate amounts of conventional excipients, mixed, dried, sterilized, filled into hard capsules, and packaged to prepare hard capsules. Each capsule contained 10 mg of ginsenoside Rg5.

[0051] Dosage and Administration: Take this preparation twice a day, 2 capsules each time.

[0052] Treatment of diseases: Used to prevent and treat anemia, especially hemolytic anemia.

[0053] Example 3: Ginsenoside Rg5 (purchased from the market) was added with appropriate amounts of common excipients, granulated, dried, and shaped into granules. Granules were prepared in a volume of 5 g / bag, with a ginsenoside Rg5 content of 20 mg / g.

[0054] Dosage and Administration: Take this preparation twice a day, 1 bag each time.

[0055] Treatment of diseases: Used to prevent and treat anemia, especially hemolytic anemia.

[0056] Example 4: Ginsenoside Rg5 (purchased commercially) was added with an appropriate amount of a solubilizer, ground, diluted with a small amount of water, mixed, flavoring agents and preservatives added, mixed, and water added to the prescribed volume. The mixture was filtered, mixed, packaged, and sterilized to prepare an oral solution. The content of ginsenoside Rg5 in the oral solution was 1.5 mg / ml.

[0057] Dosage and Administration: Take this preparation twice a day, 10-20 ml each time.

[0058] Treatment condition: A health product for patients with anemia.

[0059] Example 5: Ginsenoside Rg5 (purchased from the market) was added with appropriate amounts of common excipients, formed into pellets, and dried to prepare pills. Each pellet contained 10 mg of ginsenoside Rg5.

[0060] Dosage and Administration: Take this preparation twice a day, 2 pills each time.

[0061] Treatment condition: A health product for patients with anemia.

[0062] Example 6: Ginsenoside Rg5 (purchased from the market) was added with an appropriate amount of dropping pill base, mixed evenly, and dripped into pills to obtain dropping pills. Each pill contained 10 mg of ginsenoside Rg5.

[0063] Dosage and Administration: Take this preparation twice a day, 2 pills each time.

[0064] Treatment condition: A health product for patients with anemia.

Claims

1. Application of ginsenoside Rg5 in the preparation of products for the prevention and treatment of anemia.

2. Application of ginsenoside Rg5 in the preparation of products for the prevention and treatment of hemolytic anemia.

3. The use of ginsenoside Rg5 as claimed in claim 2 in the preparation of a product for preventing, treating and improving hemolytic anemia, characterized in that: The prevention and treatment of hemolytic anemia is specifically manifested in increasing the staining intensity of cardiac red blood cells.

4. Use of ginsenoside Rg5 according to any one of claims 1 to 3 in the preparation of a product for preventing and treating hemolytic anemia, characterized in that: The molecular formula of the ginsenoside Rg5 is: 42 H 70 O 12 , molecular weight: 766.998, structural formula:

5. The use according to claim 1 or 2, characterized in that: The products include medicines or health products.

6. The use according to claim 5, characterized in that: The preparation method of the product is to combine ginsenoside Rg5 with acceptable excipients in medicine, and process them according to conventional methods to prepare corresponding pharmaceutical preparations or health products.

7. The use according to claim 6, characterized in that: The dosage forms of the product include tablets, capsules, granules, oral liquids or pills.

8. A product for preventing and treating hemolytic anemia, characterized in that: The raw materials of the product contain ginsenoside Rg5.

9. A product for preventing, treating and improving hemolytic anemia, characterized by: The product is mainly prepared from ginsenoside Rg5.

Images